Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

R. A. DeFronzo; P. R. Fleck; C. A. Wilson; Q. Mekki;

doi:10.2337/dc08-1035

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc08-1035 ◽

2008 ◽

Vol 31 (12) ◽

pp. 2315-2317 ◽

Cited By ~ 159

Author(s):

R. A. DeFronzo ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Inadequate Glycemic Control

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2008.01933.x ◽

2009 ◽

Vol 63 (1) ◽

pp. 46-55 ◽

Cited By ~ 149

Author(s):

M. A. Nauck ◽

G. C. Ellis ◽

P. R. Fleck ◽

C. A. Wilson ◽

Q. Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metformin Therapy ◽

Dipeptidyl Peptidase 4 ◽

Metformin Monotherapy ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-

Diabetes Obesity and Metabolism ◽

10.1111/dom.12866 ◽

2017 ◽

Vol 19 (5) ◽

pp. 635-643 ◽

Cited By ~ 6

Author(s):

Chang Ho Ahn ◽

Kyung Ah Han ◽

Jae Myung Yu ◽

Joo Young Nam ◽

Kyu Jeung Ahn ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Combination Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.007 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1556-1568 ◽

Cited By ~ 354

Author(s):

Julio Rosenstock ◽

Ronald Brazg ◽

Paula J. Andryuk ◽

Kaifeng Lu ◽

Peter Stein

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Parallel Group Study ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Parallel Group

Download Full-text

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in K orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12424 ◽

2015 ◽

Vol 17 (3) ◽

pp. 309-312 ◽

Cited By ~ 22

Author(s):

M. K. Kim ◽

E.‐J. Rhee ◽

K. A. Han ◽

A. C. Woo ◽

M.‐K. Lee ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care ◽

10.2337/dc12-0706 ◽

2012 ◽

Vol 36 (2) ◽

pp. 237-244 ◽

Cited By ~ 120

Author(s):

J. B. McGill ◽

L. Sloan ◽

J. Newman ◽

S. Patel ◽

C. Sauce ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2011.01391.x ◽

2011 ◽

Vol 13 (7) ◽

pp. 653-661 ◽

Cited By ~ 117

Author(s):

R. Gomis ◽

R.-M. Espadero ◽

R. Jones ◽

H. J. Woerle ◽

K. A. Dugi

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination Therapy ◽

Initial Combination

Download Full-text

Faculty Opinions recommendation of Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717961956.793465689 ◽

2012 ◽

Author(s):

Pierre Ronco ◽

Jean-Jacques Boffa

Keyword(s):

Type 2 Diabetes ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy

Download Full-text